ePrints

Epigenetic cancer therapies: DNA methyltransferase inhibitors

Lookup NU author(s): Dr Gordon Strathdee

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Human cancers frequently show altered patterns of DNA methylation, particularly at CpG islands. These CpG islands are sequences of DNA rich in CpG dinucleotides and are often found close to gene promoters. Methylation within islands has been shown to be associated with transcriptional repression of the linked gene. Genes involved in all facets of tumour development and progression can become methylated and epigenetically silenced. Re-expression of such silenced genes can lead to suppression of tumour growth or sensitisation to anticancer therapies. Agents that can reverse DNA methylation include nucleoside and non-nucleoside inhibitors of DNA methyltransferase. Such agents are now undergoing preclinical evaluation and clinical trials in cancer patients.

Publication metadata

Author(s): Strathdee G; Brown R

Publication type: Article

Publication status: Published

Journal: Expert Opinion on Investigational Drugs

Year: 2002

Volume: 11

Issue: 6

Pages: 747-754

ISSN (print): 1354-3784

ISSN (electronic): 1744-7658

Publisher: Informa Healthcare

URL: http://dx.doi.org/10.1517/13543784.11.6.747

DOI: 10.1517/13543784.11.6.747

Altmetrics

Share